This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07710768 |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 44 participants |
| Design | Interventional, Non Randomized, Sequential, Masking: None |
| Conditions | Obesity; Overweight |
| Interventions | UBT251; Cocktail (Warfarin/Caffeine/Midazolam) |
| Start | Jul 15, 2026 |
| Primary completion | Apr 7, 2027 |
| Study completion | Apr 7, 2027 |
| Results posted | Not yet |
| Registry last updated | Aug 18, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| AUC0-u221e,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose | From pre-dose on Day 1 up to 156 days |
| AUC0-u221e,caffeine : The area under the plasma caffeine concentration-time curve extrapolated to infinity after single dose | From pre-dose on Day 1 up to 156 days |
| AUC0-u221e,midazolam: The area under the midazolam concentration-time curve extrapolated to infinity after single dose | From pre-dose on Day 1 up to 156 days |
3 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
- UBT251 Safety, Tolerability and Efficacy in Overweight or Obesity (Novo Nordisk Phase 2) (Phase 2 NCT07395687)
- UBT251 Injection Phase II Clinical Study (CKD) (Phase 2 NCT07134335)
- UBT251 Injection Phase II Study (Overweight or Obesity) (Phase 2 NCT07177469)
- A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the (Phase 1 NCT07710729)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
